Prevention of early acute rejection with daclizumab and triple immunosuppression in cadaveric renal allograft recipients

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 3, 2005, Pages 262-264

  Kandus, Aljoša ^a   Grego, Katarina ^a   Bren, Andrej F ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Daclizumab; Immunosuppression; Kidney transplantation

Indexed keywords

CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DACLIZUMAB; DILTIAZEM; HLA A ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3;

ACUTE GRAFT REJECTION; ADULT; AGED; CADAVER KIDNEY; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CADAVER; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SAFETY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 23244466043     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00268.x     Document Type: Conference Paper

References (8)

1. Vincenti F, Lantz M, Birnbaum J et al. A phase I trial of humanized anti-interleukin-2 receptor antibody in renal transplantation. Transplantation 1997;63:33-8.
2. Vincenti F, Pace D, Birnbaum J et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003;3:50-2.
3. Nashan B, Light S, Hardie I et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999;67:110-15.
4. Bumgardner GL, Hardie I, Johnson RWG et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001;72:839-45.
5. Ekberg H, Bäckman L, Tufveson G et al. Zenapax (Daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transplant Proc 1999;31:267-8.
6. Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
7. Soltero L, Carbajal H, Sarkissian N et al. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience. Transplantation 2004;78:1560-3.
8. Kovač D, Kandus A, Kotnik V et al. Anti-CD25 monoclonal antibodies in kidney transplantation. Transplantation 2004;78:276-7.